CTRI/2022/12/047818招募中未知
A prospective, open label, single arm, multicenter, interventional, study to assess the efficacy and tolerability of early enteral nutrition in hospitalized patients
Dr Reddys Laboratories0 个研究点目标入组 0 人开始时间: 待定最近更新:
试验速览
- 阶段
- 未知
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1) To study the impact of tube feeding supplement for achieving the target Macro Nutrients levels
- •2) To study the number of days required to reach the target Macro Nutrients levels
排除标准
- •1) To study the impact of EN supplement on total protein, micronutrient levels such as Zn, Vitamin C, Mg, potassium and Phosphorous.
- •2) To study the impact of tube feeding supplement events of abdominal pain, distension, vomiting and diarrhea after EN supplement
- •3) To assess the number and reasons of interruptions during the tube feeding and ease of titration of the formula
- •4) To assess the impact of tube feeding supplement on hematological parameters from baseline to the end of the study.
- •5) To evaluate the palatability of the formulation in patients shifted to ward’s, through oral supplementation
研究者
相似试验
进行中（未招募）
2 期
A Japanese Phase 2 study of 177Lu-PSMA-617 in participants with PSMA(+) mCRPCProstate CancerJPRN-jRCT2041210123Kazuyuki Suzuki28
招募中
Unknown
A prospective study to evaluate the safety and the efficacy of blood pressure reduction of Laparoscopic RDN in patients with resistant hypertensioDiseases of the circulatory systemKCT0009209DeepQure10
进行中（未招募）
4 期
A study to evaluate the safety and efficacy of Nutricharge Glycem Tablet administered with Nutricharge Glycem Prodiet in Pre-diabetic subjectsCTRI/2017/10/010007Trophic Wellness Private Limited
尚未招募
4 期
Clinical study assessing safety and effectiveness of medicine containing two antiemetic drugs (Fosnetupitant 235 mg and Palonosetron 0.25 mg) when they are administered intravenously to prevent nausea and vomiting in cancer patients receiving chemotherapy cycles.CTRI/2023/04/051951Glenmark Pharmaceuticals Limited
已完成
3 期
Trial to evaluate 3mg dose of Covid Vaccine of Cadila healthcare LimitedCTRI/2021/10/037137Cadila Healthcare Limited3,000